Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP1 and amylin analogues owenhaskins Dec 19, 2025 2 min read Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition
Tell your healthcare provider if you have changes in vision during treatment with Wegovy Increased heart rate
Pharmacological studies For assessment of drug effects under room temperature (22 2 C), male age-matched mice were double housed and fed with a 58% HFD (D12331, Research Diets) for approximately 20 weeks, followed by random assignment into groups of matched genotype, body weight and body composition
Understanding your genetic predispositions helps you and your PlexusDx clinician plan your treatment trajectory more precisely
Whether youre battling obesity, pre-diabetes, or simply want to achieve a healthier body composition, these prescription weight loss injections offered at Ewing Weight Loss Clinic in Reno can provide the solution youve been searching for
Scientific Overview A synthetic 13-amino acid linear melanocortin analog studied for receptor binding affinity, melanin production pathways, and signaling activity in research models